Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $8.06 billion. The enterprise value is $8.43 billion.
| Market Cap | 8.06B |
| Enterprise Value | 8.43B |
Important Dates
The next estimated earnings date is Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | May 19, 2025 |
Share Statistics
Bio-Techne has 156.77 million shares outstanding. The number of shares has decreased by -0.30% in one year.
| Current Share Class | 156.77M |
| Shares Outstanding | 156.77M |
| Shares Change (YoY) | -0.30% |
| Shares Change (QoQ) | -1.05% |
| Owned by Insiders (%) | 1.07% |
| Owned by Institutions (%) | 105.25% |
| Float | 154.95M |
Valuation Ratios
The trailing PE ratio is 61.95 and the forward PE ratio is 25.70. Bio-Techne's PEG ratio is 1.89.
| PE Ratio | 61.95 |
| Forward PE | 25.70 |
| PS Ratio | 6.88 |
| Forward PS | 6.30 |
| PB Ratio | 4.09 |
| P/TBV Ratio | 13.44 |
| P/FCF Ratio | 36.88 |
| P/OCF Ratio | 30.74 |
| PEG Ratio | 1.89 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.16, with an EV/FCF ratio of 38.17.
| EV / Earnings | 64.00 |
| EV / Sales | 6.97 |
| EV / EBITDA | 29.16 |
| EV / EBIT | 37.49 |
| EV / FCF | 38.17 |
Financial Position
The company has a current ratio of 3.71, with a Debt / Equity ratio of 0.21.
| Current Ratio | 3.71 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 1.36 |
| Debt / FCF | 1.92 |
| Interest Coverage | 25.42 |
Financial Efficiency
Return on equity (ROE) is 6.53% and return on invested capital (ROIC) is 5.67%.
| Return on Equity (ROE) | 6.53% |
| Return on Assets (ROA) | 5.24% |
| Return on Invested Capital (ROIC) | 5.67% |
| Return on Capital Employed (ROCE) | 9.08% |
| Revenue Per Employee | $396,318 |
| Profits Per Employee | $43,162 |
| Employee Count | 3,050 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.20 |
Taxes
In the past 12 months, Bio-Techne has paid $31.32 million in taxes.
| Income Tax | 31.32M |
| Effective Tax Rate | 19.21% |
Stock Price Statistics
The stock price has decreased by -32.54% in the last 52 weeks. The beta is 1.38, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | -32.54% |
| 50-Day Moving Average | 50.33 |
| 200-Day Moving Average | 63.61 |
| Relative Strength Index (RSI) | 51.81 |
| Average Volume (20 Days) | 1,902,961 |
Short Selling Information
The latest short interest is 6.32 million, so 4.03% of the outstanding shares have been sold short.
| Short Interest | 6.32M |
| Short Previous Month | 6.14M |
| Short % of Shares Out | 4.03% |
| Short % of Float | 4.08% |
| Short Ratio (days to cover) | 2.40 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.21 billion and earned $131.64 million in profits. Earnings per share was $0.83.
| Revenue | 1.21B |
| Gross Profit | 801.67M |
| Operating Income | 224.71M |
| Pretax Income | 232.35M |
| Net Income | 131.64M |
| EBITDA | 288.96M |
| EBIT | 224.71M |
| Earnings Per Share (EPS) | $0.83 |
Balance Sheet
The company has $140.67 million in cash and $423.50 million in debt, giving a net cash position of -$282.83 million or -$1.80 per share.
| Cash & Cash Equivalents | 140.67M |
| Total Debt | 423.50M |
| Net Cash | -282.83M |
| Net Cash Per Share | -$1.80 |
| Equity (Book Value) | 2.02B |
| Book Value Per Share | 12.87 |
| Working Capital | 458.04M |
Cash Flow
In the last 12 months, operating cash flow was $264.85 million and capital expenditures -$44.10 million, giving a free cash flow of $220.76 million.
| Operating Cash Flow | 264.85M |
| Capital Expenditures | -44.10M |
| Free Cash Flow | 220.76M |
| FCF Per Share | $1.41 |
Margins
Gross margin is 66.32%, with operating and profit margins of 18.59% and 10.89%.
| Gross Margin | 66.32% |
| Operating Margin | 18.59% |
| Pretax Margin | 13.48% |
| Profit Margin | 10.89% |
| EBITDA Margin | 23.91% |
| EBIT Margin | 18.59% |
| FCF Margin | 18.26% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.62%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.62% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 38.55% |
| Buyback Yield | 0.30% |
| Shareholder Yield | 0.92% |
| Earnings Yield | 1.62% |
| FCF Yield | 2.71% |
Analyst Forecast
The average price target for Bio-Techne is $70.00, which is 36.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $70.00 |
| Price Target Difference | 36.13% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 9.42% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 12.57 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.57 |
| Piotroski F-Score | 6 |